Coronary Bioresorbable Scaffolds Nearly as Safe and Effective as Conventional Metal Stents for Heart Disease

title
Gregg Stone, MD,FACC, FSCAI

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI). 

These are significant findings from a global clinical trial led by a researcher from the Icahn School of Medicine at Mount Sinai. The work could lead to advancements and improvements in new BVS technology and future clinical use among interventional cardiologists across the United States. 

This multi-center trial is the largest trial to examine the long-term safety and effectiveness of PCI using Abbott’s “Absorb BVS,” a novel stent made of absorbable polymer (plastic-like material).. It shows this treatment option, when properly implanted, may lead to long-term outcomes for heart disease patients that are similar to conventional treatment with metallic drug-eluting stents. 

The five-year results from the “ABSORB IV” trial were announced Wednesday, May 17, in a Late Breaking Clinical Trials/Hotline session at the EuroPCR meeting in Paris, the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and simultaneously published in the Journal of the American College of Cardiology.

Learn More

See Article